127 results
8-K
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
directed to up to five collaboration targets and (ii) personalized therapies utilizing αβ T-cell receptors (TCRs) isolated from a patient
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
therapy will not be a Competing Therapy where it only targets or is approved for treatment of indications which are different from those in relation
8-K
EX-99.1
18p849h0 kpagk
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.2
y93fir 31g
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
widgn
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-99.1
gadv8i
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
u2k ebshvnqf8fko
30 May 23
Business combination disclosure
4:21pm
8-K
n3mz8790g1g4
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
upvaydnhugtdnw
22 May 23
Business combination disclosure
7:01am
8-K
7z1c1fm2s63xar8c7
22 May 23
Other Events
6:59am
8-K
EX-99.1
cgmg47j3pwt
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
n79akzf8dzox74g1
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
3hhbx7b46c 10zc88
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm